Prostatic Neoplasms, Castration-Resistant
Showing 51 - 75 of 7,136
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco
Not yet recruiting
- Castrate Resistant Prostate Cancer
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 1, 2023
Castration-resistant Prostate Cancer, Metastatic Cancer Trial (Cabozantinib, Nivolumab)
Not yet recruiting
- Castration-resistant Prostate Cancer
- Metastatic Cancer
- (no location specified)
Aug 12, 2022
Prostate Cancer Trial in Tampa (Abiraterone Acetate)
Active, not recruiting
- Prostate Cancer
- Abiraterone Acetate
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 3, 2023
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma Trial in United States (MGC018, lorigerlimab)
Recruiting
- Advanced Solid Tumor
- +6 more
- vobramitamab duocarmazine
- lorigerlimab
-
Los Angeles, California
- +7 more
Jan 10, 2023
Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)
Not yet recruiting
- Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-PSMA-617 PET scan
- (no location specified)
Nov 13, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)
No longer available
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- (no location specified)
Jan 12, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- (no location specified)
Aug 16, 2023
Metastatic Castration Resistant Prostate Cancer Trial in China (AC176)
Not yet recruiting
- Metastatic Castration Resistant Prostate Cancer
-
Beijing, China
- +4 more
Jan 4, 2023
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer Trial in Portland (drug, procedure, other)
Not yet recruiting
- Castration Resistant Prostate Cancer
- Castration Sensitive Prostate Cancer
- Piflufolastat
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 16, 2023
Metastatic Castration-resistant Prostate Cancer, mCRPC, Prostate Cancer Trial in Melbourne (Lutetium-177 PSMA-I&T, Radium-223)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- +2 more
- Lutetium-177 PSMA-I&T
- Radium-223
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Sep 26, 2022
Castration-resistant Prostate Cancer Trial in Los Angeles (Apalutamide, Carotuximab)
Not yet recruiting
- Castration-resistant Prostate Cancer
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Sep 6, 2022
Prostate Cancer, Prostate Cancer Metastatic Trial in La Jolla (Abivertinib, Abiraterone)
Recruiting
- Prostate Cancer
- Prostate Cancer Metastatic
-
La Jolla, California
- +1 more
Feb 2, 2023
Oligometastatic Disease, Prostatic Cancer, Castration-Resistant Trial in Dresden (local ablative radiotherapy)
Recruiting
- Oligometastatic Disease
- Prostatic Cancer, Castration-Resistant
- local ablative radiotherapy
-
Dresden, Saxony, GermanyDepartment of Radiotherapy and Radiation Oncology, Faculty of Me
Aug 18, 2021
Metastatic Castration-Resistant Prostate Cancer Trial (Talazoparib)
Available
- Metastatic Castration-Resistant Prostate Cancer
- (no location specified)
Dec 6, 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (Sipuleucel-T Injection)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sipuleucel-T Injection
- (no location specified)
Nov 10, 2023
Called DEAR, to Learn More About Treatment With Darolutamide,
Active, not recruiting
- Non-metastatic Castration-resistant Prostate Cancer
- Darolutamide (Nubeqa, BAY1841788)
- +2 more
-
Whippany, New JerseyBayer
Jan 13, 2023
Castration Resistant Prostate Cancer Trial run by the National Cancer Institute (NCI) (Bintrafusp alfa, N-803, BN-Brachyury)
Not yet recruiting
- Castration Resistant Prostate Cancer
- Bintrafusp alfa
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- mCRPC
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Jul 20, 2022
Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)
Not yet recruiting
- Prostate Cancer Metastatic
- Pembrolizumab
- +2 more
- (no location specified)
Sep 29, 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in Bellinzona, London Borough of Sutton (Enzalutamide 40mg,
Recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Enzalutamide 40mg
- +4 more
-
Bellinzona, Switzerland
- +1 more
Nov 6, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- 225Ac-PSMA-R2
- 68Ga-PSMA-R2
- (no location specified)
Aug 8, 2023
Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)
Not yet recruiting
- Prostate Cancer
- DFMO
- +3 more
-
Baltimore, MarylandJohns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
Sep 22, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Tianjin (TABP EIC, Cyclophosphamide, fludarabine)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- TABP EIC
- +2 more
-
Tianjin, ChinaTianjin pepole's hosptial
Jul 28, 2022
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022